Home › Enlarged Prostate (BPH) › NCT05148156
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
Reduction of Urinary Toxicity of Stereotactic Body Radiation Therapy (SBRT) With Prostatic Urethral Lift (Urolift)
Who can join
Ages 50 to 99 · Men · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Subject is 50 - 99 years of age * Subject has provided informed consent * Subject has diagnosis of prostate cancer requiring SBRT * Subject is able to complete self-administered questionnaires * Subject is a surgical candidate for Urolift * Subject has a diagnosis of BPH * Medical record documentation of prostate volume from 30-80 ml by TRUS * Absence of a middle lobe Exclusion Criteria: * Life expectancy \< 2 years * Currently enrolled in or plans to enroll in any concurrent drug or device study * Concurrent androgen deprivation therapy * Has an active infection (e.g., urinary tract infection or prostatitis) * Diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome (e.g., nonbacterial chronic prostatitis) * Subject has been diagnosed with a urethral stricture or bladder neck contracture within the last 180 days * Subject has been diagnosed with 2 or more urethral strictures and/or bladder neck contractures within 5 years * Diagnosis of lichen sclerosis * Neurogenic bladder or other neurologic disorder that affects bladder function * Diagnosis of polyneuropathy (e.g., diabetic) * History of lower urinary tract surgery * Subject has diagnosis of stress urinary incontinence that requires treatment or daily pad or device use * Subject has been catheterized or has a PVR \> 400 ml in the 14 days prior to the surgical procedure * Current diagnosis of bladder stones
About the study
Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dysuria, and nocturia. The investigator hypothesizes that Urolift, which represents a novel minimally invasive therapy, may reduce acute and long-term urinary toxicity and side effects of radiation therapy (SBRT).
What is being tested
- Urolift (device)
Sponsor: Northwell Health · Participants: 20 · Started: Feb 11, 2026
Contact the study team
- Jennifer Polo, CCRC · Phone: 516-628-5910
Official record on ClinicalTrials.gov — NCT05148156
Locations in the U.S.
| New York | Northwell Health, Syosset |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.